glutaramic acid

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Pancreatitis 11/01/1986 - "CR 1409, a glutaramic acid derivative with competitive cholecystokinin-antagonistic activity, was administered IP and evaluated in comparison with proglumide (the model CCK-receptor antagonist), gabexate (protease inhibitor) and PGE2 (cytoprotective) on two different models of experimental pancreatitis. "
2.	Hepatocellular Carcinoma (Hepatoma) 01/01/1993 - "Preliminary screening results revealed that 2-(syn-exo-7-oxabicyclo [2.2.1] heptane-2,3-dicarboxylic imido)-N-phenyl glutaramic acid exhibited a fairly apparent inhibitory activity against human-hepatoma cells in vitro (inhibitory rate 39.4% at 0.025 mumol/ml)."

1.	Gabexate (Foy)
2.	Dinoprostone (PGE2)
3.	Cholecystokinin Receptors (Cholecystokinin Receptor)
4.	Protease Inhibitors (Protease Inhibitor)
5.	Proglumide (Milid)
6.	Heptanes
7.	Cholecystokinin (Pancreozymin)
8.	lorglumide